Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy.
BACKGROUND
It is well documented that highly active antiretroviral therapy (HAART) restores systemic immunity to human immunodeficiency virus (HIV) but the effect of this treatment on the mucosal immune system is less clear.


OBJECTIVE
Because future preventive or therapeutic vaccines against HIV may be administered by the mucosal route, we wished to evaluate the effect of HAART on the activation level and homeostasis of the intestinal B cell system.


METHODS
Duodenal biopsy specimens were collected consecutively from infection prone HIV positive adults (n = 31), mostly with advanced AIDS. In situ two colour immunofluorescence staining was performed to quantify mucosal immunoglobulin (Ig) class and subclass producing immunocytes (plasmablasts and plasma cells).


RESULTS
HIV positive patients had, on average, duodenal proportions of IgA (74.6%), IgM (19.5%), and IgG (3.4%) immunocytes similar to median values recorded in 11 HIV seronegative healthy controls but the total immunocyte number per mucosal section length unit (500 microm) was significantly increased in patients (median 175 v 120 cells/unit; p<0.008), mainly comprised of IgA (p<0.02) and IgG1 (median 81.8% of total IgG; p<0.02) isotypes. Patients receiving a successful HAART regimen tended to normalise their IgG1 proportion and showed significantly lower total duodenal IgA immunocyte number than those receiving no or insufficient antiretroviral treatment (p<0.005).


CONCLUSIONS
Our study demonstrated that advanced AIDS patients hyperactivate their intestinal B cell system. HAART could significantly reverse this perturbation, suggesting restored ability of the mucosal immune system to control intestinal infections.
Nilssen
D E
DE
Laboratory for Immunohistochemistry and Immunopathology (LIIPAT), Institute of Pathology, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway.
Øktedalen
O
O
Brandtzaeg
P
P
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology; D023241:Antiretroviral Therapy, Highly Active; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D018791:CD4 Lymphocyte Count; D004386:Duodenum / Q000187:drug effects / Q000276:immunology; D005260:Female; D020276:HIV Long-Term Survivors; D015497:HIV-1; D006801:Humans; D018928:Immunity, Mucosal / Q000187:drug effects; D007136:Immunoglobulins / Q000097:blood; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D019562:Viral Load; D001613:beta 2-Microglobulin / Q000097:blood
D019380:Anti-HIV Agents; D007136:Immunoglobulins; D001613:beta 2-Microglobulin